Stavanger University Hospital HF

The medical center is at the forefront of neuro-oncology research, focusing on innovative treatments for glioblastoma, a highly aggressive brain tumor. The center's research aims to enhance the median overall survival of patients through novel therapeutic approaches.

• Valganciclovir as an adjunct therapy
• Postoperative treatment strategies
• Survival rate improvement

By integrating valganciclovir with standard therapies, the center is pioneering efforts to extend patient survival and improve quality of life.

Specializing in the management of viral respiratory tract infections, the center conducts pivotal research on the efficacy and safety of discontinuing antibiotic therapy in patients with viral infections. This research is crucial in addressing antibiotic resistance and optimizing treatment protocols.

• Antibiotic discontinuation strategies
• Safety and efficacy assessments
• Non-inferiority trials

The center's work in this area is instrumental in shaping future guidelines for the treatment of viral infections, reducing unnecessary antibiotic use.

Focusing on primary adrenal insufficiency, the center is dedicated to improving patient outcomes through the evaluation of different treatment regimens. The research compares the impact of Plenadren versus conventional cortisone on patients' health-related quality of life.

• Quality of life assessments
• Comparative treatment studies
• Longitudinal patient monitoring

Through these studies, the center aims to refine treatment approaches, enhancing the overall well-being of patients with adrenal insufficiency.